<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204633</url>
  </required_header>
  <id_info>
    <org_study_id>jth_004</org_study_id>
    <nct_id>NCT00204633</nct_id>
  </id_info>
  <brief_title>Darbepoetin Alfa in Patients With &quot;Poor Prognosis&quot; Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)</brief_title>
  <official_title>Randomized Phase II-Trial to Determine the Impact of Darbepoetin Alfa on the Frequency of RBC Transfusions in Patients With Metastatic &quot;Poor Prognosis&quot; Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP Regimen)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The aim is to determine the frequency of RBC transfusion in patients with metastatic &quot;poor
      prognosis&quot; germ cell tumor during high-dose chemotherapy (HD-VIP, level 6) with or without
      Darbepoetin alfa
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of transfusions (reduction from 90% to 65%)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with no transfusions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>developing of hemoglobin levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective remission rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free- and overall-survival (pfs, os)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <enrollment type="Actual">108</enrollment>
  <condition>Dysgerminoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poor prognosis&quot; according IGCCCG-criteria:

          -  Primary mediastinal tumor

          -  Gonadal/retroperitoneal germ cell tumor with visceral metastases except of lung

          -  Poor marker: AFP &gt; 10.000 ng/ml or beta-HCG &gt; 10.000 ng/ml (50.000 IU/l) andd LDH &gt;10
             x upper normal limit

          -  No previous chemotherapy

          -  Age &gt; 18 years

          -  Performance-Status: WHO =&lt; 2

          -  Written informed consent

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Hemolysis

          -  Hematological disease with insufficient erythropoiesis

          -  Patients without sufficient treatment of sideropenia, folate deficiency or vitamin B12
             deficiency

          -  Uncontrolled arterial hypertension

          -  Treatment with rh-Erythropoetin during trial

          -  Creatinin clearance &lt; 50 ml/min

          -  Insufficient bone marrow function (WBC count &lt; 3.000/ml or platelets &lt; 100.000/Âµl)

          -  Other major symptomatic or uncontrolled illnesses not allowing to complete treatment
             protocol with the exception of symptoms caused by the primary disease

          -  Second malignancy, except of completely resected basal cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg T. Hartmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South West German Cancer Center, Medical Center II, University of Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center II, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 13, 2009</last_update_submitted>
  <last_update_submitted_qc>February 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Dysgerminoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

